Search Within

Pedram Razavi

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (62)
  2. Journal Article (59)
  3. Research Letter (2)
  4. Editorial (1)
Groups
  1. Breast Medicine Service (124)
  2. Department of Medicine (124)
  3. GSK Faculty (124)
  4. Human Oncology and Pathogenesis Program (124)
  5. Solid Tumor Oncology Division (124)
  6. Weinberg Fellows (124)

More Groups

People
  1. Sarat Chandarlapaty (75)
  2. Jorge Reis-Filho (56)
  3. Michael Berger (45)
  4. David Solit (37)
  5. Bob Li (32)
  6. Marc Ladanyi (31)

More People

Years
  1. 2025 (6)
  2. 2024 (17)
  3. 2023 (7)
  4. 2022 (17)
  5. 2021 (11)
  6. 2020 (27)

More Years

Publications
  1. Journal of Clinical Oncology (25)
  2. Cancer Research (23)
  3. Annals of Oncology (7)
  4. Modern Pathology (7)
  5. Nature Medicine (6)
  6. Cancer Cell (5)

More Publications

Publishers
  1. American Association for Cancer Research (32)
  2. American Society of Clinical Oncology (29)
  3. Nature Publishing Group (24)
  4. Nature Research (9)
  5. Cell Press (8)
  6. Oxford University Press (7)

More Publishers

Results (124)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial
    Meeting Abstract

    Li, B. T.; Shen, R.; Offin, M.; Buonocore, D. J.; Myers, M. L.; Venkatesh, A.; Razavi, P.; Ginsberg, M. S.; Ulaner, G. A.; Solit, D. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC)
    Meeting Abstract

    dos Anjos, C. H.; Razavi, P.; Herbert, J.; Colon, J.; Gill, K.; Modi, S.; Bromberg, J.; Dang, C. T.; Liu, D.; Norton, L.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer
    Meeting Abstract

    Toska, E.; Xu, G.; Chhangawala, S.; Cocco, E.; Razavi, P.; Otto, J.; Cai, Y.; Chan, C.; D'Avino, D. R.; Collings, C.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Genomic profiling of metastatic breast cancer identifies the Hippo pathway to be a key determinant of CDK4/6 inhibitor sensitivity
    Meeting Abstract

    Razavi, P.; Li, Q.; Li, Z.; Brown, D. N.; Ping, C.; Shen, R.; Sanchez-Vega, F.; Schultz, N. D.; Baselga, J.; Scaltriti, M.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation
    Meeting Abstract

    Cocco, E.; Kulick, A.; Misale, S.; Yaeger, R.; Razavi, P.; Won, H. H.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; Cownie, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Meeting Abstract

    Li, Q.; Razavi, P.; Li, Z.; Da Cruz Paula, A. F.; Brogi, E.; Scaltriti, M.; Reis, J. S.; Chandarlapaty, S.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAPK pathway activation
    Research Letter

    Cocco, E.; Schram, A. M.; Kulick, A.; Misale, S.; Won, H. H.; Yaeger, R.; Razavi, P.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Non-canonical, clinical ESR1 mutations promote resistance to antiestrogen therapies
    Meeting Abstract

    Toy, W.; Carlson, K. E.; Martin, T. A.; Razavi, P.; Berger, M.; Baselga, J.; Greene, G.; Katzenellenbogen, J.; Chandarlapaty, S.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: Results from the Actionable Genome Consortium
    Journal Article

    Li, B. T.; Janku, F.; Jung, B.; Hou, C.; Madwani, K.; Alden, R.; Razavi, P.; Reis-Filho, J. S.; Shen, R.; Isbell, J. M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Cyclin e mRNA: Assessing cyclin-dependent kinase (CDK) activation state to elucidate breast cancer resistance to CDK4/6 Inhibitors
    Editorial

    Chandarlapaty, S.; Razavi, P.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save